ILiAD Biotechnologies Scores $42.8M
Summary
WESTON, FL, ILiAD Biotechnologies today announced the closing of a $42.8 million Class D round of financing. ILiAD Biotechnologies, a clinical stage biotech company developing the worlds most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing. These funds will enable the company to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection. With the addition of the Class D financing, over $100 million in cumulative funding has now been secured for the development of BPZE1. The company is developing and acquiring key technologies, working with leading scientists to overcome the limitations of current vaccines, investigating the impact of B. pertussis in a range of human disease, and is focused on validating its proprietary vaccines in human clinical trials.